Part II: The Lung Cancer Workroom

Moderator(s)

• 

  Mara Antonoff, MD (she/her/hers)

  Associate Professor, Program Director of Education
  UT MD Anderson Cancer Center
  Houston, Texas, United States

  Disclosure(s): BMS, AZ, Merck, Ethicon: Advisory Board (Ongoing), Consultant (Ongoing), Speaker (Ongoing)
• 

  Jessica Donington, MD (she/her/hers)

  Chief Thoracic Surgery
  University of Chicago
  Chicago, Illinois, United States

  Disclosure(s): Amgen: Advisory Board (Ongoing); Astra Zeneca global: Advisory Board (Ongoing), Speaker (Ongoing); BMS: Advisory Board (Ongoing), Speaker (Ongoing); Merck: Advisory Board (Ongoing), Speaker (Ongoing); Roche Genentech: Advisory Board (Ongoing), Speaker (Ongoing)

Team 1(s)

• 

  Drew Moghanaki, MD, MPH

  Professor, Chief of Thoracic Oncology
  UCLA Dept of Oncology
  Santa Monica, California, United States

  Disclosure(s): Astra Zenica: Advisory Board (Ongoing), Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Varian Medical Systems: Speaker (Ongoing)
• 

  Karen Reckamp, MD (she/her/hers)

  Director, Division of Medical Oncology
  Cedars Sinai
  Los Angeles, California, United States

  Disclosure(s): AstraZeneca, Blueprint, Boehringer Ingelheim, Daiichi Sankyo, Genentech, GlaxoSmithKline, Janssen, Lilly, Mirati, Novartis, Novocure: Consultant (Terminated, September 11, 2024); Genentech; Blueprint; Daiichi Sankyo; Elevation Oncology; Janssen: research funding to institution (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)
• 

  Dan Raz, MD MAS (he/him/his)

  Professor
  City of Hope
  Duarte, California, United States

  Disclosure(s): Genentech: Advisory Board (Ongoing)
• 

  David Cooke, MD (he/him/his)

  Professor & Chief, Division of General Thoracic Surgery; Physician in Chief Comprehensive Cancer Center
  University of California, Davis Health
  Sacramento, California, United States

  Disclosure(s): Bristol Myers Squibb: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Intuitive Surgical: In kind education support; Food (Ongoing); Oxford University Press: Royalties (Ongoing)

Team 2(s)

• 

  Percy Lee, MD (he/him/his)

  Professor & Vice-Chair, Medical Director of Orange County and Coastal Regions
  City of Hope National Medical Center
  Irvine, California, United States

  Disclosure(s): AstraZeneca: Advisory Board (Ongoing), Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Genentech: Consultant (Ongoing); ImmuneSensor: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated); Johnson & Johnson: Advisory Board (Ongoing), Consultant (Ongoing); Roche: Consultant (Ongoing); RTOG Foundation: Consultant (Terminated); Varian: Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)
• 

  Amy Cummings, MD PhD (she/her/hers)

  UCLA
  Rossmoor, California, United States

  Disclosure(s): Astra Zeneca: Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); OncoHost: Consultant (Ongoing), Speaker (Ongoing); Tempus: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker (Ongoing)
• 

  Kiran Lagisetty, MD

  Assistant Professor of Surgery
  University of Michigan
  Ann Arbor, Michigan, United States

  Disclosure(s): AtriCure: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)
• 

  Loretta Erhunmwunsee, MD (she/her/hers)

  Associate Professor
  City of Hope Medical Center
  Pasadena, California, United States

  Disclosure(s): Astrazeneca: Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker (Ongoing); Bristol Myers Squibb Foundation: Advisory Board (Ongoing)

Case-Based Team Debates – strict time limits and rules:
• 4 minutes for each side
• no more than 5 slides
• 1 minute rebuttal
• have attendees vote at the end via audience-response system.

Presentations:

• 3:30pm - 3:35pm PT

  Introduction
  

  Invited Speaker: Mara B. Antonoff, MD (she/her/hers) – UT MD Anderson Cancer Center
• 3:35pm - 3:50pm PT

  Debate 1: Stage 1—Wedge vs SBRT
• 3:50pm - 4:05pm PT

  Debate 2: Stage II—Upfront Surgery and Adjuvant Therapy vs. Neoadjuvant Therapy and Surgery for cII NSCLC
• 4:05pm - 4:20pm PT

  Debate 3—Stage III: Definitive Chemoradiation and Immunotherapy vs. Neoadjuvant Therapy and Surgery for Stage III
• 4:20pm - 4:35pm PT

  Debate 4—Stage IV: LCT vs. No LCT for Stage IV Oligometastatic on TKI